Novo Nordisk (NVO), which develops weight-loss drugs, looks poised to perform well over the short term, Rebecca Walser, the founder and principal of Walser Wealth Management, told Schwab Network recently.
Walser also identified semiconductor equipment maker Lam Research (LRCX) as a good pick for the near term.
Khosro/Shutterstock.com
Why Walser Is Bullish on NVO
NVO is 57% below its all-time high, and President Donald Trump recently directed his administration to work with Congress to increase the amount of time that drugs can be sold to Medicare without the government negotiating the prices to 13 years from nine years, Walser reported. The extra four years of “proprietary pricing” that NVO could receive from Congress for its weight-loss drugs would meaningfully help the company, according to the wealth-management professional.
Meanwhile, NVO has a dividend yield of 2.4%, she pointed out.
Why Walser Is Upbeat on LRCX
Lam Research is 40% below its all-time highs and has “a decent growth trajectory,” the wealth-management professional said. She suggested that LRCX could make a positive announcement or deliver strong earnings in the near term. The company is expected to unveil its quarterly earnings tomorrow.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires
This article is originally published at Insider Monkey.
